NCI-60

The screening procedure is called the NCI-60 Human Tumor Cell Lines Screen, and it is one of the Discovery & Development Services of NCI's Developmental Therapeutics Program (DTP). The screening rates for each cell line the cytostatic and cytotoxic impact of tested substances. The same panel is used in the Molecular Target Program for the characterization of molecular targets. Measurements include protein levels, RNA measurements, mutation status and enzyme activity levels. == Cell Lines ==

The panel holds cell lines representing leukemia, melanoma, non-small-cell lung carcinoma, and cancers of the brain, ovary, breast, colon, kidney, and prostate. 13 additional cell lines are evaluated for use in the screening program, among them two lines deriving from so far not represented small-cell lung carcinoma. All cell lines but one () are available to other laboratories, including the additional cell lines. == Misidentification and Misclassification ==

Starting around the turn of the millennium, several cell lines were found to be misidentified or misclassified at the time of investigation or earlier: MDA-MB-435, originally classified as breast cancer cell line, was identified as being a melanoma cell line. It includes the cell lines reported above, although usually with reporting dates and articles considerably later than the first dates and articles rising specific concern regarding the respective cell line. Similar is true for other misidentified cell lines. == List of NCI-60 Cell Lines ==

== List of Additional Cell Lines ==